185 related articles for article (PubMed ID: 21322780)
1. Iron overload and allogeneic hematopoietic stem-cell transplantation.
Kanda J; Kawabata H; Chao NJ
Expert Rev Hematol; 2011 Feb; 4(1):71-80. PubMed ID: 21322780
[TBL] [Abstract][Full Text] [Related]
2. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.
Inati A; Kahale M; Sbeiti N; Cappellini MD; Taher AT; Koussa S; Nasr TA; Musallam KM; Abbas HA; Porter JB
Pediatr Blood Cancer; 2017 Jan; 64(1):188-196. PubMed ID: 27576370
[TBL] [Abstract][Full Text] [Related]
3. Current Review of Iron Overload and Related Complications in Hematopoietic Stem Cell Transplantation.
Atilla E; Toprak SK; Demirer T
Turk J Haematol; 2017 Mar; 34(1):1-9. PubMed ID: 27956374
[TBL] [Abstract][Full Text] [Related]
4. Iron mobilization using chelation and phlebotomy.
Flaten TP; Aaseth J; Andersen O; Kontoghiorghes GJ
J Trace Elem Med Biol; 2012 Jun; 26(2-3):127-30. PubMed ID: 22565013
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT).
Sivgin S; Eser B; Bahcebasi S; Kaynar L; Kurnaz F; Uzer E; Pala C; Deniz K; Ozturk A; Cetin M; Unal A
Ann Hematol; 2012 May; 91(5):743-749. PubMed ID: 22051904
[TBL] [Abstract][Full Text] [Related]
6. [Post transfusionnal iron overload].
Rose C
Rev Prat; 2006 Dec; 56(19):2141-5. PubMed ID: 17416052
[TBL] [Abstract][Full Text] [Related]
7. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
McLeod C; Fleeman N; Kirkham J; Bagust A; Boland A; Chu P; Dickson R; Dundar Y; Greenhalgh J; Modell B; Olujohungbe A; Telfer P; Walley T
Health Technol Assess; 2009 Jan; 13(1):iii-iv, ix-xi, 1-121. PubMed ID: 19068191
[TBL] [Abstract][Full Text] [Related]
8. How I treat transfusional iron overload.
Hoffbrand AV; Taher A; Cappellini MD
Blood; 2012 Nov; 120(18):3657-69. PubMed ID: 22919029
[TBL] [Abstract][Full Text] [Related]
9. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
Meerpohl JJ; Antes G; Rücker G; Fleeman N; Niemeyer C; Bassler D
Cochrane Database Syst Rev; 2010 Aug; (8):CD007477. PubMed ID: 20687088
[TBL] [Abstract][Full Text] [Related]
10. Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.
Vallejo C; Batlle M; Vázquez L; Solano C; Sampol A; Duarte R; Hernández D; López J; Rovira M; Jiménez S; Valcárcel D; Belloch V; Jiménez M; Jarque I;
Haematologica; 2014 Oct; 99(10):1632-7. PubMed ID: 24997153
[TBL] [Abstract][Full Text] [Related]
11. A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors.
Majhail NS; Lazarus HM; Burns LJ
Biol Blood Marrow Transplant; 2010 Jun; 16(6):832-7. PubMed ID: 20079863
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Hagag AA; Hamam MA; Taha OA; Hazaa SM
Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
[TBL] [Abstract][Full Text] [Related]
13. Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy.
Bring P; Partovi N; Ford JA; Yoshida EM
Pharmacotherapy; 2008 Mar; 28(3):331-42. PubMed ID: 18294113
[TBL] [Abstract][Full Text] [Related]
14. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
Kontoghiorghes GJ; Eracleous E; Economides C; Kolnagou A
Curr Med Chem; 2005; 12(23):2663-81. PubMed ID: 16305464
[TBL] [Abstract][Full Text] [Related]
15. The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload.
Sivgin S; Baldane S; Akyol G; Keklik M; Kaynar L; Kurnaz F; Pala C; Zararsiz G; Cetin M; Eser B; Unal A
Transfus Apher Sci; 2013 Oct; 49(2):295-301. PubMed ID: 23916904
[TBL] [Abstract][Full Text] [Related]
16. Treating iron overload: the state of the art.
Hershko C
Semin Hematol; 2005 Apr; 42(2 Suppl 1):S2-4. PubMed ID: 15846582
[No Abstract] [Full Text] [Related]
17. Deferasirox for managing iron overload in people with thalassaemia.
Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831
[TBL] [Abstract][Full Text] [Related]
18. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
Pepe A; Meloni A; Capra M; Cianciulli P; Prossomariti L; Malaventura C; Putti MC; Lippi A; Romeo MA; Bisconte MG; Filosa A; Caruso V; Quarta A; Pitrolo L; Missere M; Midiri M; Rossi G; Positano V; Lombardi M; Maggio A
Haematologica; 2011 Jan; 96(1):41-7. PubMed ID: 20884710
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
20. Korean guideline for iron chelation therapy in transfusion-induced iron overload.
Jang JH; Lee JH; Yoon SS; Jo DY; Kim HJ; Chung J; Lee JW;
J Korean Med Sci; 2013 Nov; 28(11):1563-72. PubMed ID: 24265517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]